The estimated Net Worth of Jarrod Longcor is at least $783 Thousand dollars as of 28 December 2020. Mr. Longcor owns over 29,630 units of Cellectar Biosciences Inc stock worth over $213,489 and over the last 8 years he sold CLRB stock worth over $30,680. In addition, he makes $539,303 as Chief Business Officer at Cellectar Biosciences Inc.
Sign up
Mr. Longcor CLRB stock SEC Form 4 insiders trading
Jarrod has made over 8 trades of the Cellectar Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 29,630 units of CLRB stock worth $40,001 on 28 December 2020.
The largest trade he's ever made was buying 65,218 units of Cellectar Biosciences Inc stock on 5 June 2020 worth over $75,001. On average, Jarrod trades about 5,548 units every 46 days since 2016. As of 28 December 2020 he still owns at least 102,148 units of Cellectar Biosciences Inc stock.
You can see the complete history of Mr. Longcor stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jarrod Longcor biography
Jarrod Longcor serves as Chief Business Officer of the Company. Mr. Longcor was appointed Chief Business Officer of Cellectar in September 2017. He previously served as Senior Vice President of Corporate Development and Operations since July 2016. Mr. Longcor brings years of pharmaceutical and biotech experience to Cellectar and was previously the Chief Business Officer for Avillion LLP. In this role, he was responsible for executing the company’s unique co-development partnership strategy. Prior to Avillion, Jarrod was the Vice President of Corporate Development for Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics) where he was responsible for identifying and concluding several critical collaborations for the company, including a major discovery collaboration with Sanofi Aventis valued over $700M. Prior to Rib-X, Mr. Longcor held key positions in several small to midsized biotech companies where he was responsible for business development, strategic planning and operations. Jarrod holds a B.S. from Dickinson College, a M.S. from Boston University School of Medicine and an M.B.A. from Saint Joseph’s University’s Haub School of Business.
What is the salary of Jarrod Longcor?
As the Chief Business Officer of Cellectar Biosciences Inc, the total compensation of Jarrod Longcor at Cellectar Biosciences Inc is $539,303. There are 2 executives at Cellectar Biosciences Inc getting paid more, with James Caruso having the highest compensation of $934,460.
How old is Jarrod Longcor?
Jarrod Longcor is 47, he's been the Chief Business Officer of Cellectar Biosciences Inc since 2017. There are 10 older and no younger executives at Cellectar Biosciences Inc. The oldest executive at Cellectar Biosciences Inc is Frederick Driscoll, 69, who is the Independent Director.
What's Jarrod Longcor's mailing address?
Jarrod's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932.
Insiders trading at Cellectar Biosciences Inc
Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over $1,263,511 worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth $3,966,598 . The most active insiders traders include Austin W & Greenhouse David..., Investment Company, Inc. Awm, and John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of $126,821. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth $26,000.
What does Cellectar Biosciences Inc do?
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
What does Cellectar Biosciences Inc's logo look like?
Complete history of Mr. Longcor stock trades at Cellectar Biosciences Inc
Cellectar Biosciences Inc executives and stock owners
Cellectar Biosciences Inc executives and other stock owners filed with the SEC include:
-
James Caruso,
President, Chief Executive Officer, Director -
James V. Caruso,
Pres, CEO & Director -
Jarrod Longcor,
Chief Business Officer -
Jarrod Longcor,
Chief Operating Officer -
John Friend,
Vice President, Chief Medical Officer -
Dov Elefant,
Chief Financial Officer, Vice President -
Douglas Swirsky,
Independent Chairman of the Board -
John Neis,
Independent Director -
Stefan Loren,
Independent Director -
Stephen Hill,
Independent Director -
Frederick Driscoll,
Independent Director -
Gregory J. Lynch Esq.,
Sec. -
Dr. Laurence Reilly L.L.M., LL.M, M.D., MBChB,
Interim Chief Medical Officer -
Chad J. Kolean CPA, CPA,
Chief Financial Officer -
Richard Hertzberg,
-
Brian M Posner,
Chief Financial Officer -
Igor D Grachev,
Chief Medical Officer -
Jamey P Weichert,
Chief Scientific Officer -
Paul L Berns,
Director -
Investment Company, Inc. Awm,
10% owner -
John Patrick Genn,
VP of Business Development -
Cameron Szakacs,
VP of Clinical Development -
Simon Pedder,
President and CEO -
Austin W & Greenhouse David...,
10% owner -
Asher Chanan Khan,
Director -
Chad J Kolean,
Chief Financial Officer -
Darrell Shane Lea,
Chief Commercial Officer -
Andrei Shustov,
Senior Vice President, Medical